ST-Elevation Myocardial Infarction and COVID-19 Pneumonia: The Importance of Risk-Stratification of Myocardial Injury in COVID-19 Era | Zendy

Julio C. SauzaSosa | Zendy; Óscar Millán-Iturbe | Zendy; Jorge Mendoza-Ramírez | Zendy; Carlos N. Velazquez-Gutiérrez | Zendy; Erika Lizeth De la Cruz Reyna | Zendy; Alfredo Gutierrez-Marin | Zendy; Jorge A. Fernandez-Tapia | Zendy

Open Access

ST-Elevation Myocardial Infarction and COVID-19 Pneumonia: The Importance of Risk-Stratification of Myocardial Injury in COVID-19 Era

Author(s) -

Julio C. SauzaSosa,

Óscar Millán-Iturbe,

Jorge Mendoza-Ramírez,

Carlos N. Velazquez-Gutiérrez,

Erika Lizeth De la Cruz Reyna,

Alfredo Gutierrez-Marin,

Jorge A. Fernandez-Tapia

Publication year - 2021

Publication title -

indian journal of clinical cardiology

Language(s) - English

Resource type - Journals

eISSN - 2632-4644

pISSN - 2632-4636

DOI - 10.1177/2632463621992389

Subject(s) - medicine , myocardial infarction , risk stratification , cardiology , covid-19 , angioplasty , pneumonia , disease , infectious disease (medical specialty)

Background: Myocardial injury is a common manifestation in patients with coronavirus disease (COVID-19), and the correlation with adverse outcomes has been demonstrated; therefore, adequate monitoring of myocardial injury markers is very important.Case Summary: A patient with COVID-19 was hospitalized in our hospital with an initial classification of intermediate risk for myocardial injury, after serial measurements of myocardial injury markers, risk was readjusted to high, as shown later by electrocardiographic abnormalities. The patient underwent emergency diagnostic coronary angiography and successful angioplasty. The patient was discharged to home.Discussion: Myocardial injury risk-stratification is essential in patients with COVID-19, since it is essential in the recognition of patients who are susceptible to cardiovascular complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research